Description: Axonis Therapeutics is a Boston-based biotechnology company developing first- and best-in-class neuromedicines targeting KCC2.
About Us Executive Team Board of Directors Scientific Advisory Board Our Science Our Approach Target Biology: KCC2 Platform & Pipeline News Contact us Reviving Neurons Restoring Control We are an exceptional team of drug hunters and target biology experts on a mission to improve the lives of people suffering from neurological disorders. Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibition
In October 2024, Axonis announced the closing of an oversubscribed $115 million Series A financing co-led by Cormorant Asset Management and venBio Partners, with significant investments from Sofinnova Investments, MRL Ventures Fund and Perceptive Advisors. Previously, Axonis raised $34+M in dilutive Seed funding and $8+M in competitive non-dilutive grants/awards. First-in-human trials will begin in 2024 for the first-in-class oral KCC2 potentiator drug, AXN-027, designed for restoring functional inhibition
Copyright © 2025 Axonis Therapeutics | All rights reserved. | Design by Reaves Projects.